Post-test

Managing Anemia in Chemotherapy

Post Test
A score of 70% must be achieved to receive continuing education credits.

1.

Who was the first to publish evidence-based clinical practice guidelines for the use of epoetin.
a. The American Society of Clinical Oncology (ASCO)
b. The American Society of Hematology (ASH)
c. Both A & B
d. Neither A & B

2.

Which of the following are included in American Society of Clinical Oncology 2007 Categories of Recommendations for use of Epoetin and Darbepoetin.
a. Dosage
b. Assessing Causes of anemia
c. Hemoglobin Target
d. All of the above

3.

ESA Therapy is a treatment option to decrease hemoglobin and increase transfusions for patients with chemotherapy-induced anemia.
True
False

4.

ASCO recommendations include conducting a diagnostic test for patients with:
a. Chronic lymphocytic leukemia
b. Elderly individuals with Non-Hodgkin’s lymphoma
c. History of auto-immune disease
d.All of the above

5.

Patients with high risk of thromboembolic events should:
a. Minimize use of epoetin or darbepoetin
b. Minimize use of epoetin or maximize darbepoetin
c. Minimize use of epoetin and darbepoetin
d. Maximize use of epoetin or darbopoetin

6.

Recommendations say to use caution and clinical judgment for those at risk of thromboembolic risk such as:
a. Surgery
b. Prolonged periods of immobilization or limited activity
c. Both A & B
d. Neither A & B

7

The FDA approved a starting dose of Epoetin and Darbepoetin of:
a. 125 units/kg three times a week/2.00 microgram/kg weekly
b. 150 units/kg three times a week/2.25 microgram/kg weekly
c. 175 units/kg three times a week/2.50 microgram/kg weekly
d. 200 units/kg three times a week/2.75 microgram/kg weekly

8

If a patient has no response to treatment investigate for:
a. Underlying tumor progression
b. Iron deficiency
c. Other etiologies of anemia
d. All of the above

9

Do not use ESAs to treat anemia associated with malignancy, or the anemia of cancer, among patients with either solid or non-myeloid hematological malignancies who are not receiving concurrent chemotherapy.
True
False

10

Recommendations for patients with Myeloma, Non-Hodgkin’s lymphoma, Chronic lymphocytic leukemia include:
a. Begin treatment with chemotherapy and/or corticosteroids
b. Observe the hematologic outcomes achieved solely through tumor reduction first
c. Both A & B
d. Neither A & B

Activity Evaluation

Please rate this activity on the following scale:
4 - Excellent 3 - Good 2 - Fair 1 - Poor

Due to the content of this activity, I will change my practice patterns by:

	Providing appropriate education to patients
	Follow guidelines provided by ASCO & ASH
	Follow the recommendations given by ASCO
	My practice patterns will not change
	Other Specify:

Continuing education implies quality improvement in behavior. As part of our quality improvement process, NAMCP/AAMCN will contact you 6 months from your post test submission to monitor change.